FDA Approved Weekly Insulin for Children 10+: What the 18-Patient Study Shows

Short answer: On October 23, 2026, the U.S. FDA approved once-weekly basal insulin Awiqli (insulin icodec-abae) for people aged 10 years and older with type 2 diabetes. That does not mean every child using daily insulin can switch immediately. The pediatric evidence centered on 18 participants who received one dose, and the approval does not cover type 1 diabetes.

What exactly did FDA approve?

Awiqli is a long-acting basal insulin injected under the skin once a week. FDA had previously approved it for adults with type 2 diabetes and has now extended the U.S. indication to patients age 10 and older.

“Once weekly” refers to the basal-insulin schedule. It does not necessarily replace mealtime insulin or every other glucose-lowering medicine. It also does not mean that a patient can copy the numerical dose from a daily insulin product. Switching requires product-specific calculations, monitoring and clinical supervision.

How much pediatric evidence was direct?

The pediatric study cited by FDA enrolled 18 participants aged 10 years and older with type 2 diabetes. Each participant received a single dose of insulin icodec so investigators could measure how the drug entered and remained in the bloodstream. Absorption after the first dose was faster in the pediatric participants than in adults, but pharmacometric modeling predicted that exposure would resemble adult exposure after the first few weekly doses.

In the original paper, the participants’ mean age was 14.4 years and all were already using insulin at screening. The study was descriptive and did not use a formal statistical sample-size calculation. Researchers observed single-dose concentrations and modeled what repeated weekly dosing might look like at steady state.

Six adverse events were reported in two participants; all were mild and resolved. One level 1 hypoglycemia episode occurred, and there were no serious or severe adverse events. A study of this size and duration cannot reliably detect uncommon harms or establish long-term safety.

What did the study not test?

This was not a long-term randomized trial comparing weekly versus daily basal insulin in children. It did not directly establish pediatric differences in HbA1c, severe hypoglycemia, adherence, school-day burden or quality of life over months or years.

FDA explains that the pediatric decision also used adequate and well-controlled adult type 2 diabetes studies and adult safety data. Pediatric effectiveness was expected from the similarity of modeled drug exposure after repeated dosing. The approval therefore reflects an evidence bridge between adults and children, not a claim that 18 children proved every clinical outcome.

Why is a self-directed switch risky?

Changing basal insulin requires review of the current product and dose, mealtime insulin, glucose records, kidney and liver function, prior hypoglycemia and daily routine. With a weekly medicine, one dosing error can influence glucose for several days. FDA specifically advises checking the product label and the dose displayed on the pen before every injection.

Hypoglycemia remains the main insulin risk. Severe episodes can cause seizures, unconsciousness, life-threatening complications or death. FDA also warns about medication errors and accidental overdose, hyperglycemia, low potassium, and fluid retention or heart failure when insulin is combined with a thiazolidinedione.

Do not stop or convert an existing insulin regimen using a calculation from an article. The prescriber must decide whether weekly basal insulin fits the patient and how the transition should be monitored.

Who is outside this approval?

• Type 1 diabetes: The pediatric FDA indication discussed here is for type 2 diabetes only.
• Children younger than 10: They are outside the approved age range.
• People outside the United States: FDA approval does not determine another country’s authorization, reimbursement or availability.
• Individual dose decisions: A weekly schedule alone cannot determine a safe starting or conversion dose.

Important limits

• Direct pediatric evidence came from a small, 18-person, single-dose study.
• Steady-state exposure was partly modeled rather than observed through a long pediatric treatment trial.
• The study did not compare long-term glycemic outcomes, adherence or quality of life against daily basal insulin in children.
• All participants were already using insulin, and the group had a high mean BMI, limiting generalization to every young person with type 2 diabetes.
• Approval and access can differ substantially by country.

The useful takeaway

The practical change is a new U.S. basal-insulin option for people age 10 and older with type 2 diabetes. Fewer basal injections may be valuable, but the direct pediatric evidence was pharmacokinetic and small. Families should not interpret “once weekly” as “simple to switch,” or extend the indication to type 1 diabetes or younger children. A clinician must use the current label, the patient’s glucose data and the full treatment plan to decide whether and how to change insulin.

---

Primary sources

• U.S. FDA: FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients (October 23, 2026)
• ClinicalTrials.gov: NCT05790681
• Van Name et al., Pediatric Diabetes: Pharmacokinetic Properties of Once-Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes

Prepared by: Life Choice Note, an independent personal health-information explainer · Reviewed: October 27, 2026

This article provides general information and does not direct an insulin switch or dose adjustment. Treatment changes require a prescribing clinician and the current authorization information for the relevant country.